6826 Stock Overview
Shanghai Haohai Biological Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 6826 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$26.70 |
| 52 Week High | HK$42.95 |
| 52 Week Low | HK$21.71 |
| Beta | 0.77 |
| 1 Month Change | -5.65% |
| 3 Month Change | -12.46% |
| 1 Year Change | -0.053% |
| 3 Year Change | -24.94% |
| 5 Year Change | -16.09% |
| Change since IPO | -35.99% |
Recent News & Updates
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Shareholder Returns
| 6826 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.3% | -3.9% | -0.5% |
| 1Y | -0.05% | -5.7% | 19.9% |
Return vs Industry: 6826 exceeded the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 6826 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 6826 volatility | |
|---|---|
| 6826 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 6826 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6826's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,179 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 6826 fundamental statistics | |
|---|---|
| Market cap | HK$13.71b |
| Earnings (TTM) | HK$458.48m |
| Revenue (TTM) | HK$2.93b |
13.4x
P/E Ratio2.1x
P/S RatioIs 6826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6826 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.75b |
| Cost of Revenue | CN¥848.86m |
| Gross Profit | CN¥1.90b |
| Other Expenses | CN¥1.47b |
| Earnings | CN¥430.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 69.10% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 7.0% |
How did 6826 perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield85%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Haohai Biological Technology Co., Ltd. is covered by 17 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jingwei Qi | China Merchants Securities Co. Ltd. |
| Xiaofang Xu | Citic Securities Co., Ltd. |
| Eva Zhao | Citigroup Inc |